Why BGMS Stock Traded Steady Today — RQD Quant Desk Flash

The Roarable RQD rating is 36 out of 100, graded D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow" (). The score is built from five pillars, each weighted out of 20:

• Fundamental cash engine: 4 / 20. this pillar reflects ROIC of -35% and an FCF yield of 0%. For a prospective investor, this is the weakest pillar: the business is not currently generating returns on invested capital or free cash flow that would support the equity valuation.
• Whale / 13F flow: 7 / 20. The rating covers institutional accumulation and options positioning. The holders section contains no institutional data, so the score cannot be traced to specific filings in this dossier. Investors should treat this pillar as weakly supported.
• Insider conviction: 5 / 20. this reflects SEC Form 4 and Congressional PTR cluster flow.
• Macro regime fit: 10 / 20. beta is 1.0 with sector sensitivity noted. A beta of 1.0 implies market-level volatility, but the score is held down by the company's weak fundamentals rather than by beta alone.
• Forensic balance sheet: 10 / 20. Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. These sit in a middle-to-weak range and indicate balance sheet vulnerability rather than a crisis-level condition.

Taken together, the score points to a stock where the upside case depends on a reversal in cash generation that the reported figures do not yet show. A prospective investor should weigh the very small market capitalization and the sharp recent price decline (-9.79%) against the absence of profitability.

Bio Green Med Solution Inc. Is a NASDAQ-listed company in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry (per the company profile). Reported revenue is — in each listed fiscal year (), so the company's current income-generating activity cannot be characterized from the provided material.

The company reported zero revenue and operating losses across all three periods, with negative free cash flow in each. Gross, operating, and net margins are each 0% (per the market data), and ROIC is -35%. The FY 2023 net income figure of $22.6M sits against an operating loss of -$25. The Altman Z-Score of 2.5 and Piotroski F-Score of 2/9 () suggest a weak balance sheet, and Debt/Equity is 0.5. Debt values are listed as N/A for every period, so the leverage figure cannot be reconciled with the period-level data.

• 🐂 Primary Bull Case: The stock trades at $0.83 with a market cap of $5.5M and a Roarable RQD score that is still assigned a 10/20 macro fit pillar on a beta of 1.0. With Fundamental Cash Engine at 4/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 9/20, sustained execution supports upside toward the top of the $0.57 – $2.80 52-week range.
• 🐻 Primary Bear Case: Reported revenue is $0.0M in every period, ROIC is -35%, and FCF is negative in each year, with a Piotroski F-Score of 2/9. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), BGMS carries a macro regime beta of 1.00 and gross margin of —.

• Key Question #1: What explains the FY 2023 net income of $22.6M against an operating loss of -$25.5M?
• Key Question #2: What are the terms and size of the "Future NRG" transaction referenced as a dilution risk?
• Key Question #3: What is the cash runway, given FY 2025 cash of $3.5M against FCF of -$4.8M?